Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD
Published in The lancet oncology (01.08.2012)
Published in The lancet oncology (01.08.2012)
Get full text
Journal Article